Stocktoria
Tango Therapeutics, Inc. TNGX
Tango Therapeutics, Inc. (TNGX) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $62.4M at a -162.9% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-06-29 | Canaccord Genuity | Buy (main) |
| 2026-06-26 | Jefferies | Buy (up) |
| 2026-06-11 | Canaccord Genuity | Buy (main) |
| 2026-06-09 | HC Wainwright & Co. | Buy (main) |
| 2026-06-09 | Canaccord Genuity | Buy (main) |
| 2026-06-08 | Leerink Partners | Outperform (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.833 |
| Retained earnings / assets | -1.513 |
| EBIT / assets | -0.279 |
| Equity / liabilities | 6.593 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| TNGX | Tango Therapeutics, Inc. | 3/9 | 5.58 | — | +48.3% |
| NUVB | Nuvation Bio Inc. | 3/9 | -2.01 | — | — |
| FBIO | Fortress Biotech, Inc. | 4/9 | -12.29 | 13.5 | +9.7% |
| ENTA | ENANTA PHARMACEUTICALS INC | 4/9 | -2.79 | — | -3.4% |
| AYTU | AYTU BIOPHARMA, INC | 4/9 | -8.14 | — | +1.8% |
| SPRO | Spero Therapeutics, Inc. | 4/9 | -8.9 | 15.3 | +39.2% |
| KURA | Kura Oncology, Inc. | 2/9 | -2.37 | — | +25.2% |
About Tango Therapeutics, Inc.
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
FAQ
Is TNGX financially healthy?
Tango Therapeutics, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does TNGX pay a dividend?
No, Tango Therapeutics, Inc. does not currently pay a dividend.
How profitable is TNGX?
In FY2025, Tango Therapeutics, Inc. had a net margin of -162.9% and a return on equity of -29.3%.
What is the analyst price target for TNGX?
The average Wall-Street price target for Tango Therapeutics, Inc. is $43.82, about 71.3% above the recent price, from 11 analysts (consensus: strong buy).
Is TNGX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Tango Therapeutics, Inc.: a Piotroski F-score of 3/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.